EGFR and non-small cell lung carcinoma: In the large Japanese Lung Cancer Registry study of patients with lung cancer diagnosed in 2012, the 3-year survival rate was only 17% for those with NSCLC who received chemotherapy but no EGFR tyrosine kinase inhibitor, suggestive of no actionable genomic alterations as in the present study [5].